Amgen/Genetics Institute
Executive Summary
EPO patent dispute will most likely continue through September and into October, Amgen said. The company is just completing the defense of its '008 EPO patent. In the next couple of weeks Amgen will argue against Genetics Institute's '0195 patent. A decision is expected by late November.